Financial Performance - Total revenue for the third quarter was RMB 316,386,319, a decrease of 34.87% compared to the same period last year[9]. - Net profit attributable to shareholders was RMB 19,773,669, down 80.11% year-on-year[9]. - Basic earnings per share decreased by 76.92% to RMB 0.03[9]. - Operating revenue decreased by 26.23% year-to-date due to market competition and a decline in sales order prices[16]. - Total profit increased by 242.54% year-to-date, primarily due to a decrease in gross profit and the dual impact of changes in the fair value of biological assets[16]. - Net profit attributable to shareholders increased by 214.79% year-to-date, influenced by lower gross profit and changes in the fair value of biological assets[16]. - Total profit for the current reporting period decreased by 81.85%, primarily due to compressed profit margins from sales orders and decreased contributions from laboratory services[17]. - Net profit attributable to shareholders for the current reporting period decreased by 80.11%, influenced by similar factors affecting total profit[17]. - The net profit from laboratory services for the year-to-date period was a loss of RMB 156,891,000, a significant decrease of 9,101.32% year-on-year[12]. - The net profit excluding non-recurring gains and losses for the year-to-date period was RMB 29,044,731, a decrease of 92.94%[9]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 9,533,382,709, an increase of 1.46% from the previous year[9]. - The total liabilities increased to RMB 1.41 billion as of September 30, 2025, compared to RMB 1.32 billion at the end of 2024[25]. - The total non-current assets decreased to RMB 4.22 billion from RMB 4.36 billion, showing a decline of approximately 3.2%[24]. - The company's fixed assets increased to RMB 780.36 million from RMB 696.79 million, reflecting a growth of about 12%[24]. - The contract liabilities rose to RMB 978.97 million from RMB 827.16 million, indicating a growth of approximately 18.4%[25]. Cash Flow - The company's cash flow from operating activities for the year-to-date period was RMB 266,391,149, an increase of 38.51%[9]. - Net cash flow from operating activities increased by 38.51% year-to-date, mainly due to a decrease in cash payments for goods and taxes[16]. - Operating cash inflow for the first three quarters of 2025 was CNY 1,323,471,987.19, a decrease of 3.2% compared to CNY 1,367,691,390.73 in the same period of 2024[35]. - Cash inflow from investment activities totaled CNY 1,966,983,491.98, down 21.5% from CNY 2,508,098,115.21 in 2024[36]. - Net cash flow from investment activities was negative at CNY -264,722,612.49, an improvement from CNY -950,050,766.71 in the previous year[36]. - Cash outflow from financing activities decreased significantly to CNY 58,988,545.91 in 2025, compared to CNY 248,828,091.97 in 2024[37]. - The net increase in cash and cash equivalents for the first three quarters of 2025 was CNY -63,142,619.75, a notable improvement from CNY -1,013,522,516.10 in 2024[37]. - The ending balance of cash and cash equivalents as of September 2025 was CNY 902,060,508.84, down from CNY 1,840,124,511.87 in 2024[37]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 96,458[19]. - The total equity attributable to shareholders increased by 0.52% to RMB 8,120,652,590[9]. - The total equity attributable to shareholders as of September 30, 2025, was CNY 8,120,652,590.12, slightly up from CNY 8,078,818,586.72 at the end of 2024[26]. - The total liabilities and equity amounted to CNY 9,533,382,709.22 as of September 30, 2025, compared to CNY 9,396,152,610.45 at the end of 2024[26]. Income and Expenses - Total operating revenue for the first three quarters of 2025 was CNY 984,961,529.76, a decrease of 26.1% compared to CNY 1,335,156,050.40 in the same period of 2024[28]. - Total operating costs for the first three quarters of 2025 were CNY 1,025,427,901.11, down from CNY 1,227,734,251.03 in 2024, reflecting a reduction of 16.5%[28]. - The net profit for the first three quarters of 2025 was CNY 80,706,047.32, compared to a net loss of CNY 74,244,009.94 in the same period of 2024[29]. - The comprehensive income total for the first three quarters of 2025 was CNY 74,225,826.90, a significant improvement from a loss of CNY 79,103,195.69 in 2024[31]. - Basic and diluted earnings per share for the first three quarters of 2025 were both CNY 0.11, compared to a loss of CNY 0.09 per share in 2024[31]. - Other income increased to CNY 24,712,928.01 in 2025 from CNY 19,124,400.35 in 2024, marking a growth of 29.0%[29]. - Investment income decreased to CNY 20,033,342.30 in 2025 from CNY 31,620,189.62 in 2024, a decline of 36.8%[29]. - The company reported a decrease in research and development expenses to CNY 63,864,270.44 in 2025 from CNY 71,085,657.06 in 2024, a reduction of 10.0%[28].
昭衍新药(06127) - 2025 Q3 - 季度业绩